Rutgers,Emory University scientists Towards developing vaccine hepatitis C virus

Towards vaccine for hepatitis C virus

12:02 PM, 14th October 2014
Rutgers University scientists Towards developing vaccine for hepatitis C virus
A ribbon diagram of the E2 core in complex with the antigen-binding fragment.

NEW YORK, US: Hepatitis C, an infectious disease of the liver caused by the hepatitis C virus (HCV), affects 160 million people worldwide. It is spread by blood-to-blood contact that most often results from intravenous drug use, transfusions, and poorly sterilized medical equipment. Up to 80 per cent of those infected develop a chronic infection, which can lead to cirrhosis, liver cancer, and liver failure.

There is no vaccine for HCV and the few treatments that are available do not work on all variants of the virus. Before scientists can develop potential vaccines and additional therapies they must first thoroughly understand the molecular-level activity that takes place when the virus infects a host cell. Given the complexity of the process, this is a daunting venture.

A new study performed in part at the National Synchrotron Light Source by scientists from Rutgers University and the Emory University School of Medicine takes researchers a step closer to this goal. They determined the molecular structure of a protein that is directly involved in how the virus penetrates the host cell membrane. The protein is a component of the outer portion of the virus particle. The outer layer, made of HCV proteins and lipids derived from the membrane of the host cell, helps the virus enter the host cell and evade its immune system.

On HCV, there are two envelope proteins known as E1 and E2 that have roles in the infection process. This study focused on E2, which binds to the host cell and is a target for the host’s antibodies. Therefore, this interaction is a logical starting point for potential therapies. But first, scientists need to learn much more about the precise roles of E1 and E2.

“Our results provide unprecedented insights into HCV entry and will play a role in developing an HCV vaccine and new drugs to treat the disease,” said Joseph Marcotrigiano, Scientist, Rutgers’ Center for Advanced Biotechnology and Medicine.

This work is focused on one specific section of E2, known as the ectodomain core. Using x-rays, the group was able to piece together a detailed look at the core while bound to a section of the antibody produced by the host. This location on the antibody is called an antigen-binding fragment.

One aim of the study was to determine whether E2 has the features and behavior of related viral proteins, which would mean that it functions by allowing the virus to fuse to the host cell membrane so that it can release its genetic material into the cell and initiate infection. Confirming this would give researchers a leg up in determining how E2 works, but Marcotriginao and his colleagues found that E2 does not resemble a typical a viral fusion protein.

The group used two x-ray techniques to gather information on the molecular structure of E2. At NSLS beamline X25, they studied a crystal sample of E2 (a repeating ordered arrangement) using a beam of x-rays. By analyzing the pattern that results as the x-rays diffract from the crystal, the group created a three-dimensional computer model of the structure. This entire process, called x-ray crystallography, is a technique often used to determine structural information about large biological molecules, like proteins.

At the Advanced Light Source (located at Lawrence Berkeley National Laboratory), they used small-angle x-ray scattering (SAXS) to study E2 in solution. The group correlated these results with those from the crystallography study.

The x-ray studies show that E2’s ectodomain core has a compact globular shape, consisting mainly of “random coil,” a term used to describe an irregular arrangement of protein segments, long protein “beta strands,” with two small spiral-shaped protein “alpha helices.” The beta strands form two sheets, A and B, arranged perpendicular to each other. With the exception of a certain fold exhibited by sheet A, these features are not consistent with class II viral fusion proteins.

“These data provide valuable information towards defining the role of E2 and establish a foundation for further studies in understanding HCV entry and infection,” said Marcotrigiano.

© Brookhaven National Laboratory News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

ADM to buy Specialty Commodities Inc

CHICAGO, US: Archer Daniels Midland Company (ADM) announced an agreement to purchase Specialty Commodities Inc (SCI), a leading originator, processor ...

Read more
Mexico regulations extends reviews of PPG’s acquisition of Comex

PITTSBURGH, US: PPG Industries has received notice from Mexico’s Federal Economic Competition Commission that it is extending the review timelin ...

Read more
Ineos acquires majority share in second shale gas license in Scotland

FALKIRK, SCOTLAND: Petrochemical company Ineos has bought the majority share in a second license for shale gas exploration and development in Scotland ...

Read more
New way to deliver vaccines could stop tumor growth

WASHINGTON, US: Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical ca ...

Read more
Nuberg Engineering bags $15 mn chlor alkali contract in Abu Dhabi

NOIDA, INDIA: Nuberg Engineering has been awarded $15 million chlor alkali EPC project by Al Ghaith Industries in Abu Dhabi. The project is for doubli ...

Read more
Electrically conductive plastics for low cost, high efficient solar cells, batteries

WEST LAFAYETTE, US: An emerging class of electrically conductive plastics called ‘radical polymers’ may bring low-cost, transparent solar ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X